[WS(P)26] Systemic Immune Diseases

[WS26-26-O/P] Isoliquiritigenin inhibits activation of NLRP3 inflammasome with CAPS mutations by suppressing caspase-1 activation and mutant NLRP3 aggregation

^○Koudai Kani¹, Hiroe Honda², Kiyoshi Takatsu², Yoshinori Nagai¹ (1.Department of Pharmaceutical Engineering, Faculty of Engineering, Toyama Prefectural University, 2.Toyama Prefectural Institute for Pharmaceutical Research)

キーワード：

NLRP3 inflammasome、Cryopyrin-associated periodic syndromes、isoliquiritigenin、macrophage

閲覧にはパスワードが必要です

ログイン

または